The Relationship of PSA, PSAD and Clinicopathological Stage in Patients with Prostate Cancer

REFERENCES

1. ↵
   1. Stamey TA,
   2. Johnstone IM,
   3. McNeal JE, et al.

   Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167: 103-111.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Benson MC,
   2. Whang IS,
   3. Pantuck A, et al.

   Prostate specific antigen density: a means of distinguishing benign prostate hypertrophy and prostate cancer. J Urol 1992; 147: 815-816.

   OpenUrlPubMedWeb of Science
3. ↵
   1. Antenor JA,
   2. Han M,
   3. Roehl KA, et al.

   Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urology 2004; 172: 90-93.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Wolff JM,
   2. Boeckmann W,
   3. Effert PJ, et al.

   Evaluation of patients with diseases of the prostate using prostate-specific antigen density. Br J Urol 1995; 76: 41-46.

   OpenUrlPubMed
5. ↵
   1. Catalona WJ,
   2. Southwick PC,
   3. Slawin KM, et al.

   Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-260.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Freedland SJ,
   2. Wieder JA,
   3. Jack GS, et al.

   Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 2002; 168: 110-115.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Datta MW,
   2. Dhir R,
   3. Dobbin K, et al.

   Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/ml: results from the cooperative prostate cancer tissue resource. J Urol 2005; 173:546-1551.

   OpenUrl
8. ↵
   1. Stamey TA,
   2. Caldwell M,
   3. McNeal JE, et al.

   The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297-1301.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Noguchi M,
   2. Stamey TA,
   3. Neal JE, et al.

   An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000; 163: 1751-1755.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Aleman M,
    2. Karakiewicz PI,
    3. Kupelian P, et al.

    Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/ml: implications for screening. Urology 2003; 62: 70-74.

    OpenUrlCrossRefPubMed
11. ↵
    1. Freeland SJ,
    2. Aronson WJ,
    3. Kane CJ, et al.

    Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer 2004; 101: 748-753.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Gonzalez CM,
    2. Roehl KA,
    3. Antenor JV, et al.

    Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Urology 2004; 64: 723-728.

    OpenUrlCrossRefPubMedWeb of Science
13. 1. Freeland SJ,
    2. Kane CJ,
    3. Presti JC, et al.

    Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol 2003; 169: 969-973.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Sozen S,
    2. Eskicorapci S,
    3. Kupeli B, et al.

    Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study. European Urology 2005; 47: 302-307.

    OpenUrlPubMed
15. ↵
    1. Ohi M,
    2. Ito K,
    3. Suzuki K, et al.

    Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4 ng/ml. European Urology 2004; 45: 92-97.

    OpenUrlPubMed